Quantitative Aspects of Chemical Carcinogenesis and Tumor Promotion in Liver

by H. W. Kunz,* H. A. Tennekes,* R. E. Port,* M. Schwartz,* D. Lorke* and G. Schuade*

Chronic exposure of rodents to high dose levels of drugs, food additives and environmental chemicals frequently results in liver enlargement. Several of these compounds have been found to enhance the incidence of liver tumors in animals briefly exposed previously to hepatocarcinogens. Accordingly, it has been advanced that these agents act as tumor promoters. This contention has remained subject of controversy following reports that these substances may also cause liver tumors in non-carcinogen-treated rodents, particularly in those characterized by a relatively high incidence of "spontaneous" liver tumors. Since many of these chemicals are in common use, a crucial question would seem to be whether such effects are due to facilitation of the expression of pre-existing oncogenic potential, i.e., to tumor promotion, or to the synergistic action of weakly carcinogenic agents. As a result of mechanistic differences tumor promotion and syn-carcinogenesis must exhibit different dose-time-response characteristics, and, accordingly, it should be possible, in principle, to discriminate between these phenomena. However, since tumor manifestation periods in low-dose groups frequently exceed the animals average lifespan, this approach may not always yield conclusive data, unless a sensitive early marker of carcinogenic activity can be employed. There is evidence that enzyme-deficient preneoplastic areas in liver can be used for this purpose. A strong quantitative correlation between carcinogen dose, the extent of ATPase deficient areas, and the subsequent appearance of tumors has now been established for a number of hepatocarcinogens. Experimental data are consistent with the concept that two critical events (hits) are required for induction of ATPase deficiency in hepatocytes. The first hit is carcinogen-dependent, whereas the second hit would seem to be due to time-dependent event(s). Tumor-promoters, such as phenobarbital, were found to accelerate and increase formation of preneoplastic islets. This evidence, together with data indicating that the compound is devoid of carcinogenic potential, suggests that phenobarbital may be operative at relatively early stages of hepatocarcinogenesis by increasing the probability of the occurrence of the time-dependent second hit. Such effects are dose-dependent and appear to be related to the induction of liver enlargement. The changes in hepatocellular ploidy status and atypical nuclear figures observed during phenobarbital treatment and cessation thereof, suggest that this compound might induce abnormal redistributions of genetic material. It is postulated that these cytological changes may result in phenotypical manifestation of recessive oncogenic information.

Introduction

Ever since the discovery that mouse skin carcinogenesis can be enhanced by chronic application of the skin irritant croton oil (1) and the subsequent isolation and characterization of phorbol esters as active components (2), tumor promoters have proved to be useful model compounds in studies on the nature of critical steps in chemical carcinogene-

*The German Cancer Research Centre, Institute of Biochemistry, im Neuenheimer Feld 280, D-6900 Heidelberg, Germany.
and existing chemicals (7). Subsequent investigations have revealed that although different initial events may trigger this effect, liver enlargement is invariably a result of a growth response to meet increased functional demands (5, 7, 8). At the cellular level, liver enlargement is usually characterized by pronounced cellular hypertrophy and polyploidisation, and to a lesser extent by hyperplasia, i.e., cell multiplication (5, 6).

**Tumorigenesis: Carcinogens Versus Promoters**

The quantitative studies of chemical carcinogenesis (Fig. 1) pioneered by Druckrey and associates (29, 30), have established that clear relationships exist between dose, time and tumor appearance. Chemical carcinogenesis obeys the formula: (dose x time)^n = constant and, accordingly, linear regressions are obtained using logarithmic coordinates; in general, negative dose is plotted versus time. The tangent of the slope reflects the value of n, which has been termed acceleration or reinforcing factor. This factor may range considerably, from 1.1 for 4-dimethylaminoazobenzene, 2.3 for diethylaminoethylamine, 2.7 for N-nitrosomorpholine, or up to 4.0 for N-nitrosoethanolamine. It was clear from Druckrey’s experiments—and this will be further substantiated in this publication—that even in the range of relatively low dose levels, there is no detectable deviation from linearity. This evidence indicates that carcinogenic agents cause irreversible and cumulative effects in their target cells, and

![Graph showing dose-time-response relationships of chemical carcinogenesis in liver: 50% tumor mortality in rats continuously exposed to diethylnitrosamine (DENA), 4-dimethylaminoazobenzene (4-DAB), N-nitrosomorpholine (NNM), and diethanolaminoethylamine (DEtN). The graph illustrates the dose-time relationship for various chemicals, with a linear and logarithmic scale for dose and time, respectively.](image.png)
there are no indications for the existence of threshold levels. Tumor promoters, on the other hand, function by amplifying the impact of prior carcinogenic insults, and it can be envisaged that such compounds may not be operative in low dose regions. In addition, it would seem conceivable that tumor-promoting effects may reach a maximum at high dose levels.

Experimental evidence in favor of this concept can be derived from the dose-time-response characteristics of TPA (12-O-tetradecanoylphorbol-13-acetate)-mediated enhancement of mouse skin carcinogenesis (Hecker and Schmidt, personal communication) (Fig. 2). Negative TPA dose was plotted versus time, and tumor response was defined as the occurrence of a fixed percentage of papilloma-bearing animals. The analysis shows that in high dose level regions, increments in TPA dose do not appear to accelerate the appearance of tumors significantly, suggesting that as from a particular dose level of the promoter, oncogenic potential will become maximally expressed. At the other end of the scale, the evidence clearly points towards the existence of a threshold level for tumor-promoting action. Similar relationships for TPA can be derived from data previously reported by Verma and Boutwell (39). It should be possible, in principle, therefore, to discriminate between tumor promoters and carcinogens on the basis of dose time-response studies. A dose response analysis of the effects of phenobarbital on rat liver carcinogenesis (18) suggests similar, although somewhat less clearcut characteristics. It is remarkable that the acceleration of liver tumor

**FIGURE 2.** Dose time-response relationships observed with TPA (12-O-tetradecanoylphorbol-13-acetate) in 7,12-dimethylbenzanthracene DMBA-initiated skin carcinogenesis in standardized experiments with NMRI mice (Hecker and Schmidt, personal communication.)

**FIGURE 3.** Dose: median time to liver tumor relationship in female CF:1 mice exposed to dieldrin (33). Arrow indicates location of the median time to liver tumor appearance in control animals. The dotted line indicates the median survival time of control animals, 95% confidence intervals for treated (bars) and control animals (cross-hatched) are also shown.
formation in dieldrin-treated CF-1 mice (33) exhibits a dose time-response relationship strikingly similar to that seen with TPA. However, that this approach may not always yield conclusive data, since tumor manifestation periods in low dose groups may frequently exceed the animal's average lifespan. This would appear to be a general characteristic of drugs with controversial tumorigenic properties, such as dieldrin or DDT. This problem could be overcome, however, by employment of a sensitive early marker of carcinogenic activity.

**Preneoplastic Areas as Quantitative Early Markers of Liver Carcinogenesis**

In recent years, evidence has accumulated, that in the case of liver, putatively preneoplastic areas can serve this purpose (34-40). These areas, commonly called islets, are deficient in enzymes such as ATPase or glucose-6-phosphatase, and may also show glycogen storage or a positive γ-glutamyl transferase reaction, as well as considerably enhanced epoxide hydrolase levels (41). It is not clear at present whether these cellular alterations are caused by somatic mutations, and, if so, whether these mutations are directly related to the carcinogenic process. There is, however, a strong quantitative correlation between carcinogen dose, the extent of enzyme-deficient areas, and the subsequent appearance of liver tumors (10, 35, 42). The development of an arbitrarily defined extent of ATPase-deficient areas in livers of rats continuously treated with various levels of diethylnitrosamine was found to show a dose-time-response relationship with characteristics identical to that observed for the induction of liver tumors (Fig. 4). This quantitative correlation has recently been confirmed for N-nitrosomorpholine (Fig. 4). These studies have also provided evidence for the actual number of critical events, also referred to as hits, that must occur before ATPase deficiency becomes phenotypically manifest. To this end, a mathematical model was developed which takes into account parameters such as the number of susceptible liver cells, the number of critical genes per cell, the risk per unit carcinogen dose for an intact critical gene to be hit and the minimum number of hits required for induction of islet cells (43). A comparison of the expected curves for varying numbers of hits with the actual number of islets observed after exposure of rats to increasing total doses of diethylnitrosamine (constant dose level administered for periods up to 6 weeks) revealed that experimental results are consistent with the assumption that a minimum of two hits is required for the expression of the preneoplastic cell phenotype (Fig. 5). Results in support of this concept have been obtained from chronic treatment studies with N-nitrosomorpholine at various levels of exposure. The assumption that two critical hits are required for enzyme deficiency is consistent with the observed time-response relationship for islet induction in N-nitrosomorpholine hepatocarcinogenesis (Fig. 6). These data indicate that islet number is related to exposure time by a power of 2. In contrast, dose-islet number relationships show a slope characteristic of a one-hit mechanism. This latter phenomenon was also observed previously by Emmelot and Scherer (35). This evidence suggests that only the first hit is carcinogen-dependent, whereas the second hit, which leads to phenotypical manifestation of enzyme deficiency, would seem to be independent of further carcinogen treatment and caused by a time-dependent event.

**Initiation and Promotion of Liver Carcinogenesis**

These considerations explain the characteristics of islet formation following cessation of carcinogen
CHEMICAL CARCINOGENESIS AND TUMOR PROMOTION IN LIVER

FIGURE 5. Multi-hit model for the induction of ATPase-deficient cell clones in rat liver by carcinogens (43). The model equation is:

\[ E(U/D) = N \left[ \sum_{i=1}^{n} k^i \left(1 - e^{-D_i} e^{-D} \right)^{n-i} \right] \]

where \( E(U/D) \) = expected number of ATPase-deficient cell islets \( D \) per unit volume of liver tissue, at total carcinogen dose \( D \), \( N \) = total number of susceptible liver cells/unit volume, \( k \) = minimum number of hits required for expression of islet cell phenotype, \( n \) = total number of ATPase-deficient gene loci per liver cell, \( \lambda \) = probability per carcinogen dose unit for an intact ATPase-relevant gene locus to be hit. Expected curves were compared with experimental results obtained in rats exposed to 5 mg diethylnitrosamine (DENA)/kg BW/day for periods up to 6 weeks. Animals were killed and analyzed 6 weeks after the end of DENA treatment. Experimental results are consistent with the hypothesis that \( k = 2 \).

treatment, which is a necessary feature of initiation-promotion studies. Following discontinuation of diethylnitrosamine treatment, the number of preneoplastic islets continues to rise for a certain period of time, and after having reached a maximum gradually decreases until a steady-state level is established (Fig. 7). These characteristics of the preneoplastic response following cessation of carcinogen treatment have been observed by several groups and were interpreted in various ways. The finding that islet formation is initiated by a carcinogen-dependent first hit and requires a time-dependent second hit for its phenotypical manifestation may explain these characteristics on the premise that the genetic changes leading to ATPase deficiency are recessive in nature. Since the decrease in islet number usually starts after a time period similar to the reported average lifespan of hepatocytes, it is conceivable that enzyme-deficient cells are subject to physiological turnover unless they assume a more neo-plastic character. This turnover is likely to include hepatocytes with nonexpressed first hits, and this would explain the observation that no new islets are being formed in the steady-state situation (Fig. 7). Exposure to diethylnitrosamine-pretreated rats, to phenobarbital results in pronounced enhancement of the preneoplastic response (Fig. 8). During the initial stages of phenobarbital treatment, these effects were found to be due entirely to increases in the number of islets and not to any acceleration of islet cell growth. Similar to the changes observed in control animals, a maximum was reached, followed by a decline, until the number of islets remained constant. Both maximum and steady state were at considerably higher levels, however, and occurred at an earlier stage than in controls. This amplification of the preneoplastic response resulted in an early appearance of an increased number of islets with progressed neo-plastic characteristics. This was indicated by the frequent
appearance of cellular phenotypes, such as intermediate and basophilic cells, that are characteristic of later stages of hepatocarcinogenesis (44). At this time, islet size distribution in phenobarbital-treated rats showed a distinct shift to higher diameters. These results suggest that the observed enhancement of islet growth at later stages resulted from an accelerated expression of neoplastic character, and not from continuous stimulation of islet cell multiplication by the promoting drug.

The intensity of the effects of phenobarbital on the preneoplastic response was found to be dependent on the level of prior initiation. In the experiments shown in Figure 9, rats were pretreated with varying doses of diethylnitrosamine, followed or not followed by treatment with a constant dose of phenobarbital. Phenobarbital accelerates the formation of preneoplastic islets, and this suggests that the compound may be operative by amplifying the event leading to expression of the second time-dependent hit. This effect was most pronounced at the lowest level of exposure to the initiating carcinogen. Phenobarbital was increasingly ineffective the higher the level of prior initiation. This phenomenon is also illustrated in Figure 10, which includes effects observed with animals pretreated with 4 mg/kg diethylnitrosamine/day for 4 weeks. Similar results have been reported for the action of the classical tumor promoter TPA on DMBA-initiated skin carcinogenesis (47).

These results suggest that, as a general phenomenon, tumor promoters act by increasing the impact of the acceleration principle associated with time-dependent events in carcinogenesis.
Tumor Promotion in Liver: Mechanism, Dose Dependency and Toxicological Implications

Present evidence indicates that tumor promotion in liver by drugs is somehow correlated with organ enlargement. Effects on liver weight have been found to reach a plateau after a certain treatment period; in the case of phenobarbital this can usually be seen after 1 week of treatment. It follows that if proliferative processes are involved in tumor promotion, intermittent drug treatment should produce effects similar to those seen after continuous treatment. Accordingly, rats initiated with diethylnitrosamine were treated with phenobarbital for 1 week at 6-week intervals for a period of 18 weeks, and results were compared with those obtained with rats treated continuously (Fig. 11). Intermittent exposure to phenobarbital was found to result in similar, if not more pronounced increases in the number of preneoplastic islets in liver. The observation that a total phenobarbital dose of only 1/6 of that administered to continuously treated rats may exert similar enhancing effects on the preneoplastic response of liver sharply conflicts with the concept that phenobarbital acts as a weakly carcinogenic agent. However, the observation that pronounced tumor-promoting effects may

Figure 9. Effect of phenobarbital treatment on the number of ATPase-deficient islets in livers of rats pretreated with different levels of diethylnitrosamine. Experimental details as in Figure 8. The data observed in rats pretreated with 4 mg DENA/kg/day were omitted because of interference with the other curves. For the 4 mg DENA treatment group, control values were nearly identical to that seen in the treatment group DENA (2 mg) + phenobarbital. Results observed in the treatment group DENA (4 mg) + phenobarbital were slightly higher than those seen in the DENA (8 mg) controls.

DENA dose (mg/kg/day)

Figure 10. Effect of phenobarbital (PB) on diethylnitrosamine (DENA)-induced rat liver carcinogenesis: (●) DENA; (○) DENA + PB. Experimental details as in Figure 8. Carcinogenic response defined as the occurrence of 1% ATPase-deficient areas per unit liver volume. Effects of indicated daily DENA dose levels when given continuously correspond to those observed with the three levels of DENA pretreatment (2, 4 and 8 mg/kg/day for 4 weeks). The former dose levels are calculated from division of the total DENA dose administered by the number of days required for the development of 1% ATPase-deficient areas per unit liver volume (46).

Figure 11. Effects of intermittent and continuous phenobarbital treatment on the number of ATPase-deficient islets in livers of rats pretreated with diethylnitrosamine. Adult female Wistar rats were pretreated with diethylnitrosamine (50 ppm in the drinking water, equivalent to an uptake of 5 mg/kg/day) for a period of 4 weeks. One group of carcinogen pretreated animals was subsequently treated continuously with phenobarbital (0.1% in the drinking water) for 18 weeks, a second group received this dose level for only 1 week at 6-week intervals. The remaining animals served as controls.
also occur as a result of intermittent drug treatment could raise considerable problems in terms of the assessment of drug safety in the human situation.

Since the doses of phenobarbital usually employed in these animal studies exceed the therapeutic dose by several orders of magnitude, the assessment of the relevance of phenobarbital-mediated tumor promotion to humans would seem to necessitate an evaluation of dose-response characteristics. We have therefore investigated the dose-dependency of phenobarbital-mediated tumor promotion in rats (44). Quantitative analysis of number, total volume, and size distribution of ATPase-negative and γ-glutamyltransferase-positive islets indicated that significant effects were associated with a phenobarbital dose of 75 mg/kg only (Fig. 12). Smaller exposure levels caused limited effects within the control range. None of the three phenobarbital exposure levels caused any effect in livers of noninitiated animals. These latter results constitute additional evidence to indicate that the compound is devoid of carcinogenic activity. The dose-response lines, when recorded as in Figure 2, showed that in this dose region the effects approach zero. It should be noted, however, that even with a threshold dose clearly defined in rodents on the basis of these studies, risk assessments may not be realistic as long as the nature of the critical cellular events and the dose levels required to produce such effects in humans remain obscure.

In the reported dose-response study with phenobarbital, induction of the microsomal mono-oxygenase system was noted in all treatment groups, followed by dose-dependent increases in liver weight. At dose levels associated with overt tumor-promoting action, these effects were accompanied by an increased formation of hydrogen peroxide and superoxide anions in liver microsomes in vitro (unpublished observations). It is interesting to note that induction of reactive oxygen species has also been observed in livers of rats exposed to tumor-promoting drugs that fail to induce microsomal enzyme systems, such as clofibrate and halothane. The formation of reactive oxygen species is presently discussed as a critical phenomenon in TPA-mediated tumor promotion, since this effect appears to be related to the stimulation of cell proliferation, in particular of cellular polyplidization, and possibly also to the induction of sister-chromatide exchanges. A marked increase in hepatocellular ploidy status is also characteristic of drug-induced liver enlargement. Analysis of cytological parameters revealed that in the initial stages of liver enlargement, this phenomenon is due not only to DNA replication and endomitosis, but also to nuclear fusion in binucleated liver cells (Fig. 13). Following adaptation of the liver to the increased functional demands, and particularly after cessation of drug-treatment, there is a decline in the extent of

**FIGURE 12.** Effect of varying doses of phenobarbital on number and total volume of ATPase-deficient islets in livers of rats pretreated with N-nitrosomorpholine (NNM). Female Lewis rats, weighing approximately 200 g, were pretreated with NNM (120 ppm in the drinking water for a period of 7 weeks). Values indicate treatment mean (six animals/group).

**FIGURE 13.** Hepatocellular changes induced by phenobarbital. Adult female NMRI mice were continuously treated with phenobarbital (0.1% in the drinking water). All cytological parameters were quantified with light microscopy on liver sections. Ploidy histograms were measured in sections and, additionally, in isolated liver nuclei. 3H-thymidine autoradiography was carried out as described by Rabes et al. (48). DNA content of nuclei was determined by microscope fluorimetry of Feulgen-stained material. Specific radioactivity in nuclei was determined by using a Leitz microscope photometer MPV (42).
nuclear polyploidy associated with an increase in the number of polyneucleated cells. In the course of this process atypical nuclear figures are frequently observed, which may be a reflection of aberrant nuclear divisions. It is conceivable that changes in hepatocellular ploidy status leading to abnormal chromosomal redistribution could turn heterozygous mutations homozygous. In this way, recessive oncogenic information could become phenotypically manifest (second hit). This concept provides an explanation for the observed increases in the number of islets for considerable periods of time after discontinuation of carcinogen treatment and for the impact of tumor-promoting drugs on this process. The accelerated progression of the neoplastic character of islets in livers of phenobarbital-treated animals may be similarly explained.

The induction of such critical events in rodent liver necessitates high exposure levels of tumor-promoting agents usually far in excess of the levels used in the human situation. In this context, it is interesting to note that epidemiological surveys have failed to demonstrate adverse effects of protracted phenobarbital treatment on human health (49, 50). It remains conceivable, however, that some tumor-promoting drugs could trigger critical disturbances in liver cells at dose levels approaching those used in human therapy (51).

These considerations may have important general implications for the design and interpretation of animal carcinogenicity tests. Such experiments must address the question whether tumorigenic effects are due to the action of a carcinogenic agent, or to facilitation of the expression of a pre-existing endogenous, viral or environmental oncogenic factor. Since the effects of promoters would seem to be reversible and nonexistent below threshold levels, the risks associated with these compounds should be assessed on the basis of exposure levels relevant to man.

This paper is dedicated to Professor O. Westphal on the occasion of his 70th birthday.

REFERENCES

1. Berenblum, I. The cocarcinogenic action of croton resin. Cancer Res. 1: 44-48 (1941).
2. Hecker, E. Isolation and characterization of the cocarcinogenic principles from croton oil. In: Methods of Cancer Research. (H. Busch, Ed.): Vol. 6. Academic Press, New York/London, 1971, pp. 439-484.
3. Boutwell, R. K. The function and mechanism of promoters of carcinogenesis. Crit. Rev. Toxicol. 2: 419-443 (1974).
4. Conney, A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19: 317-366 (1967).
5. Kunz, W., Schaude, W., and Siess, M. Stimulation of liver growth by drugs. In: Proceedings of the European Society for the Study of Drug Toxicity, Vol. VII (International Congress Series No. 115) Excerpta Medica Foundation, Amsterdam, 1966, pp. 113-153.
6. Schulte-Herman, R. Induction of liver growth by xenobiotic compounds and other stimuli. Crit. Rev. Toxicol. 3: 97-158 (1974).
7. Golberg, L. Liver enlargement produced by drugs: its significance. In: Experimental Study of the Effects of Drugs on the Liver. (International Congress Series No. 115) Excerpta Medica Foundation, Amsterdam 1966, pp. 171-184.
8. Kunz, W., and Schnieders, B. RNA metabolism and induction of extramicrosomal enzymes during liver enlargement due to drugs. In: Proceedings IV International Congress of Pharmacology, Vol. IV, Schwabe, Basel 1970, pp. 326-340.
9. Appel, K. E., Richart, R., and Kunz, W. Influences of inducers and inhibitors of the microsomal mono-oxygenase system on the alkylating intensity of dimethylnitrosamine in mice. J. Cancer Res. Clin. Oncol., 94: 47-61 (1979).
10. Kunz, W., Appel, K. E. Schwarz, M., and Stöckle, G. Enhancement and inhibition of carcinogenic effectiveness of nitrosamines. In: Primary Liver Tumours (H. Remmer, H. M., Bolt, P. Bannasch, and H. Popper, Eds.), MTP Press, Lancaster, U.K. 1978, pp. 261-284.
11. Hoch-Ligeti, G., Argus, M. F., and Arcos, S. C. Combined carcinogenic effects of dimethylnitrosamine and 3-methylcholanthrene in rat. J. Natl. Cancer Inst. 40: 535-550 (1968).
12. Kunz, W., Schaude, G., and C. Thomas. Die Beeinflussung der Nitrosamincarcinogenese durch Phenobarbital und Halogenkohlenwasserstoffe. Z. Krebsforsch. 72: 291-304 (1969).
13. Peraino, C., Fry, R. J. M., and Staffeldt, E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in rat by 2-acetylaminofluorene. Cancer Res. 31: 1506-1512 (1971).
14. Peraino, C., Fry, R. J. M., Staffeldt, E., and Kiesielecki, W. E. Effects of varying the exposure to phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. Cancer Res. 33: 2701-2705 (1973).
15. Peraino, C., Fry, R. J. M., Staffeldt, E., and Christopher, J. P. Comparative enhancing effects of phenobarbital, amobarbital, diphenylhydantoin, and dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. Cancer Res. 35: 2884-2890 (1975).
16. Peraino, C., Fry, R. J. M., and Staffeldt, E. Effects of varying the onset and duration of exposure to phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis. Cancer Res. 37: 3623-3627 (1977).
17. Peraino, C., Fry, R. J. M., and Grube, D. D. Drug-induced enhancement of hepatic tumorigenesis. In: Mechanisms of Tumor Promotion and Carcinogenesis (T. J. Slaga, A. Sivak, and R. K. Boutwell, Eds.), Vol. 2, Raven Press, New York, 1978, pp. 421-432.
18. Peraino, C., Staffeldt, E. F., Haugen, D. S., Lombard, L. S., Stevens, F. J., and Fry, R. J. M. Effects of varying the dietary concentration of phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis. Cancer Res. 40: 3265-3273 (1980).
19. Tomatis, L., Turosov, V. Day, N., and Charles, R. T. The effects of long-term exposure to DDT on CF-1 mice. Int. J. Cancer, 10: 489-506 (1972).
20. Peraino, C., Fry, R. J. M., and Staffeldt, E. Enhancement of spontaneous hepatic tumorigenesis in C3H mice by dietary phenobarbital. J. Natl. Cancer Inst. 51: 1349-1350 (1973).
21. Walker, A. I. T., Thorpe, E., and Stevenson, D. E. The toxicology of dieodrin (HEOD). I. Long-term oral toxicity studies in mice. Food Cosmet. Toxicol., 11: 415-432 (1973).
22. Thorpe, E. Walker, A. I. T. The toxicology of Dieldrin (HEOD). II. Comparative long term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, β- BHC and γ-BHC. Food Cosmet. Toxicol., 11: 433-442 (1973).

23. Ito, N., Nagasaki, H., Aoe, H. Sugihara, S., Miyata, Y., Arai, M., and Shirai, T. Brief communication: Development of hepatocellular carcinomas in rats treated with benzene hexachloride. J. Natl. Cancer Inst. 54: 801-805 (1975).

24. Tennekes, H. A., Wright, A. S., Dix, K. M., and Koeman, J. H. The effects of dieldrin, diet and bedding on enzyme function and tumour incidence in livers of male CF-1 mice. Cancer Res. 41: 3615-3620 (1981).

25. Bidwell, K., Weber, E., Nienhold, I., Connor, T., and Legator, M. S. Comprehensive evaluation for mutagenic activity of dieldrin. Mutat. Res. 31: 314 (1975).

26. Schwarz, M., Appel, K. E. Rickart, R., and Kunz, H. W. Effect of DMN, Phenobarbitone and halothane on the sedimentation characteristics of rat liver DNA. In: Mechanisms of Toxic Action on some target organs. Arch. Toxicol (Suppl) 2: 479-482 (1979).

27. Swenberg, J. A., Petzold, G. L., and Harbach, P. R. In vitro DNA damage/alkaline elution assay for predicting carcinogenic potential. Biophys. Biochem. Res. Commun. 72: 732-738 (1976).

28. Wright, A. S., Akintonwa, D. A. A., and Wooder, M. F. Studies on the interactions of dieldrin with mammalian liver cells at the subcellular level. Ecotoxicol. Environ. Safety 1: 7-16 (1977).

29. Druckrey, H. Quantitative Aspects in Chemical Carcinogenesis. (U.I.C.C. Monographs, Vol. 7), Springer Verlag, Berlin-Heidelberg-New York, 1967, pp. 60-78.

30. Druckrey, H., Preussmann, R., Ivankovic, S. and Schmähl, D. Organotrope carcinogene Wirkungen bei 65 verschiedenen N-nitroso-Verbindungen an BD-Ratten. Z. Krebsforsch. 69: 103-201 (1967).

31. Habs, M., Preussmann, R., and Schmähl, D. Dose-response study on the carcinogenicity of N-nitrosodiethanolamine (NDELA) in male Strague-Dawley rats. Poster presented at the first SEK-Symposium, Heidelberg, 3/11-13/1981; abstract, J. Cancer Res. Clin. Oncol. 99: CH12 (1981).

32. Verma, A. K., and Boutwell, R. K. Effects of dose and duration of treatment with the tumour promoting agent, 12-0-tetradeceanoylphorol-13-acetate, on mouse skin carcinogenesis. Carcinogenesis 1: 271-276 (1980).

33. Tennekes, H. A., Edler, L., and Kunz, H. W. Dose-response analysis of the enhancement of liver tumor formation in CF-1 mice by dieldrin. Carcinogenesis 3: 941-945 (1982).

34. Bannasch, P. The cytopenia of hepatocytes during carcinogenesis. Recent Results Cancer Research, Vol. 19, Springer Verlag, Berlin-Heidelberg, 1968.

35. Emmelot, P., and Scherer, E. The first relevant cell stage in rat liver carcinogenesis: a quantitative approach. Biochim. Biophys. Acta 605: 247-304 (1980).

36. Friedrich-Freksa, H., Gössner, W., and Börner, P. Histochimische Untersuchungen der Carcinogenese in der Rattenleber nach Dauergaben von Diäthylnitrosamin. Z. Krebsforsch 72: 226-253 (1969).

37. Friedrich-Freksa, H., Paradopulo, G., and Gössner, W. Histochemische Untersuchungen der Carcinogenese in der Rattenleber nach zeitlich begrenzter Verabfolgung von Diäthylnitrosamin. Z. Krebsforsch. 72: 240-253 (1969).

38. Schauer, H., and Kunze E. Enzymhistrochemische und autoradiographische Untersuchungen während der Carcinisierung der Rattenleber mit Diäthylnitrosamin. Z. Krebsforsch. 70: 252-266 (1968).

39. Ito, H., and Kunz, W. New principle for analysis of chemical carcinogenesis. Nature 263: 701-703 (1976).

40. Pitot, H. C., Bornsness, L., Goldworthy, T., and Kitagawa, T. Biochemical characterisation of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature 271: 456-458 (1978).

41. Kuhlmann, W. D., Krischan, R., Kunz, W., Guenther, T. M., and Oesch, F. Focal elevation of liver microsomal epoxide hydrolase in early preneoplastic stages and its behaviour in the further course of hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 98: 417-423 (1981).

42. Kunz, W., Seuade, G., Schwarz, M., and Tennekes, H. Quantitative aspects of drug-mediated tumor promotion in liver and its toxicological implications. In: Carcinogenesis and Biological Effects of Tumor Promoters, Carcinogenesis, Vol. 7, Raven Press, New York, 1982, pp. 111-125.

43. Port, R. E., Rittgen, W., and Kunz, W. Multi-hot model describing the induction of ATP-ase deficient cell clones in rat liver by carcinogens. Poster presented at the first SEK-Symposium, Heidelberg, 3/11-13/1981; Abstract J. Cancer Res. Clin. Oncol. 99: A40 (1981).

44. Moore, M., Mateos, J., Kunz, W., and Bannasch, P. Cellular and subcellular analysis of effects of phenobarbitone on NNN-hepatocarcinogenesis. J. Cancer Res. Clin. Oncol. 99: A35-36 (1981).

45. Scherer, E., Hoffmann, P., Emmelot, P., and Friedrich-Freksa, H. Quantitative study on foci of altered liver cells induced in the rat by a single dose of diethylnitrosamine and partial hepatectomy. J. Natl. Cancer Inst., 49: 93-106 (1972).

46. Rajewsky, M. F., Dauber, W., and Frankenberg, H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 152: 82-85 (1966).

47. Stenback, R., Peto, R., and Shubik, P. Initiation and promotion at different ages and doses in 2,200 mice. III. Linear extrapolation from high doses may underestimate low tumour risks. Brit. J. Cancer 44: 24-34 (1981).

48. Rabes, H. M., Scholze, P., and Jantsch, B. Growth kinetics of diethylnitrosamine induced, enzyme deficient "preneo- plastic" liver cell populations in vivo and in vitro. Cancer Res. 32: 2577-2586 (1972).

49. Clemmensen, J., Fuglsang-Frederiksen, V., and Plum, C. M. Are anticonvulsants oncogetic? Lancet i: 705-707 (1974).

50. Clemmensen, J. Phenobarbitone, liver tumours, and Thoro 30-trast. Lancet i: 37-38 (1975).

51. Barich, L. L., Swarz, J., Barich, D. J., and Horowitz, M. G. Oral griseofulvin: a co-carcinogenic agent to methylchol-anthrene-induced cutaneous tumors. Cancer Res. 22: 53-55 (1962).